Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. Ku covers the...

Market Cap	$1.97B	P/E Ratio	18.72
52W High	$16.88	52W Low	$7.29
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	68.9%	52W Position	84.1%
Overall Score	71	Value Score	80
Quality Score	73	Technical Score	60

EPS Current Est	$0.82	EPS Next Est	$0.8
EPS Growth Est	-2.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUPH	$15.35	-1.22%	598.09K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUPH	$15.35	-1.2%	598.09K
3
4
5
6

AUPH

AUPH

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Aurinia Pharmaceuticals Inc Data in Excel

Get Aurinia Pharmaceuticals Inc Data in Excel